Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
  • Clinical Diagnostics Part 1: a sector poised for growth 0 comments
    Feb 16, 2010 2:57 PM

     Many of the issues coming out of the  healthcare reform discussion:  rising medical costs, Medicare budget, need for better clinical outcomes, push for biogenerics have  caused concern among investors and limited returns in the healthcare sector. Although M&A activity has picked up, funding for venture start-ups. equity for public companies and IPOs' is down to a trickle. But biotechnology is evolving particularly in genomics, robotics and cell biology. Companies in the diagnostic sector that already have the cash flow or a strong balance sheet, product sales  and platform technologies  can take advantage of this environment because diagnostic tests have become faster, better and cheaper with the added blockbuster of molecular medicine that can ultimately deliver lower costs of treatment and better clinical outcomes.

    Our 2009 Life Science Portfolio had several Diagnostic picks that had huge gains over a one year period: Abaxis (NASDAQ:ABAX) up  56% , Inverness (IMA) up 71%, and Hologic (NASDAQ:HOLX) up 36%. We still like these stocks on weakeness as they are leaders among the small caps in their markets. Other Dx companies  in the 2009 Portfolio are still at good values: GenProbe (NASDAQ:GPRO) $43.7 and tools Company Illumina (NASDAQ:ILMN) $37.

    With a view to the emerging long term technology trends in genomics and personalized medicine we see a greater need for diagnostics that can show clinical utility and cost effectiveness of treatment. This trend is already happening with Cancer (Her-2 test) and various infectious diseases such as HIV, HCV and HPV.

    Some of the diagnostic stocks to watch with strong molecular capability are :

    Genomic Health (GHDH) $17.30  Genomic based testing.

    Genoptix (GXDX) $31.90 Personalized testing

    Qiagen (NASDAQ:QGEN) $21.40 Molecular tools and Diagnostics

    Sequenom (NASDAQ:SQNM) $5.20 Genetic Analysis and SNP analysis

    More on these companies later.

    Disclosures:Raygent owns SQNM,

    Disclosure: SQNM

Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.